<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346058</url>
  </required_header>
  <id_info>
    <org_study_id>SF13136A</org_study_id>
    <nct_id>NCT02346058</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins</brief_title>
  <official_title>Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ten Sun Pharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ten Sun Pharma Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation efficacy and safety of Esarin Gel in subjects with chronic venous insufficiency or
      varicose veins combine superficial vein thrombophlebitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label,non-controlled study design with three visits (pre-treatment/baseline, treatment
      day 14 and day 28). Administered Esarin Gel twice daily for 28 days in subjects with chronic
      venous insufficiency rated between CEAP 0 and 3 or varicose veins combine superficial vein
      thrombophlebitis, in comparison to the pre-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in subject's leg swelling</measure>
    <time_frame>28 days</time_frame>
    <description>Change from pre-treatment (baseline) in the thigh circumference on treatment day 14 and day 28. Using the tape measure to measure the thigh circumference.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in subject's leg pain</measure>
    <time_frame>28 days</time_frame>
    <description>Change from pre-treatment (baseline) in subject's leg pain on treatment day 14 and day 28. For the assessment of pain, a numerical rating scale (0-10; 0(zero) meaning &quot;no pain&quot; and 10 (ten) &quot;the worst pain&quot;) is used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment through the adverse events reports</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of patient's quality of life</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement of patient's general activities, mood and sleeping from pre-treatment (baseline) to day 14 and day 28 during Esarin Gel treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Chronic Venous Insufficiency</condition>
  <condition>Varicose Vein</condition>
  <condition>Superficial Vein Thrombophlebitis</condition>
  <arm_group>
    <arm_group_label>Esarin Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.
Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.
Duration: 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esarin Gel</intervention_name>
    <arm_group_label>Esarin Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  Patients of both sexes, aged above 20 years old.

               -  The patient has confirmed his/her willingness to participate in the study, after
                  being informed about all the aspects of the study that might be relevant for
                  his/her decision to participate, and has signed and dated the informed consent
                  form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC).

               -  Presence of chronic venous insufficiency which is rated between functional
                  classes CEAP 0 and 3.(CEAP Classes: C0:no visible or palpable signs of venous
                  disease, C1:telangiectasies or reticular veins. C2 :apparent Varicose veins, C3
                  :Edema)

               -  Diagnosed with superficial vein thrombophlebitis and have skin reaction by
                  redness, swelling, fever and pain symptoms.

          2. Exclusion Criteria:

               -  Known allergy to the product's ingredients

               -  pregnant or breastfeeding

               -  patient is joining to any other clinical trail

               -  Patient has not sign the informed consent form

               -  Deep vein thrombosis

               -  Cellulitis

               -  Stasis dermatitis

               -  The patient is taking non-steroids anti-inflammatory drugs( include oral ,topical
                  creams or patch form)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung C. Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Thrombophlebitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

